Real Madrid's Kylian Mbappé in hospital with gastroenteritis at Club World Cup
Kylian Mbappé has been admitted to hospital with acute gastroenteritis, Real Madrid have said. The forward missed the team's opening game of the Club World Cup against Al-Hilal, which ended in a 1-1 draw on Wednesday.
'Our player Kylian Mbappé is suffering from an acute case of gastroenteritis and has been admitted to hospital in order to undergo a series of tests and follow the appropriate course of treatment,' Madrid said in a statement.
Madrid's manager, Xabi Alonso, had said after the Al-Hilal game that Mbappé had experienced 'significant viral issues' and that the forward would be assessed before the next game, on Sunday, against Pachuca.
More details soon …
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
35 minutes ago
- Daily Mail
EXCLUSIVE Experts finally find treatment for incurable viral infection suffered by 122million Americans
Half of Americans are suffering from an incurable disease that causes painful - and embarrassing - blisters and sores around the mouth. About 122million people have herpes simplex virus 1 (HSV-1), the oral strain of herpes. It's spread though close skin-to-skin contact and differs from the sexually transmitted herpes simplex virus 2 (HSV-2), which causes genital blisters and sores. There is no cure for HSV-1, but antiviral medications can manage outbreaks and reduce the risk of transmission. Now, however, researchers from Spain, have discovered how the virus acts on a person's DNA, opening the door for a possible cure. The team found that the virus 'hijacks' a certain enzyme in the body that allows herpes to replicate itself, but if that enzyme is blocked, it brings 'the hostile takeover to a halt.' The researchers are hopeful that the study's findings, which provide the first proof herpes actually reshapes a person's DNA within only hours of infection, may help address the public health burden of HSV-1. Globally, nearly 4billion people have this type of herpes and experts are becoming more concerned as drug-resistant strains are developing, which could lead to more transmission. And unmanaged herpes can lead to devastating complications, traveling to the brain and triggering inflammation, which can increase the risk of dementia. Researchers in Spain analyzed human cells and infected them with HSV-1, and found almost immediately that it reshapes cell DNA so it can access more genes and spread rapidly throughout the body. However, blocking the enzyme topoisomerase I, which controls DNA replication, stopped HSV-1 from rearranging genes during infection, stopping it from spreading. Blocking the enzyme can be done with drugs called topoisomerase inhibitors, which are usually used in chemotherapy regimens to stop DNA from replicating and forming more cancer cells. This could be the first-ever method of slowing the spread of HSV-1. The researchers said while more evidence supporting a possible treatment is needed, the study could be the first step in preventing worldwide herpes outbreaks. Professor Pia Cosma, corresponding study author and researcher at the Centre for Genomic Regulation (CRG) in Barcelona, said: 'In cell culture, inhibiting this enzyme stopped the infection before the virus could make a single new particle. 'That gives us a potential new therapeutic target to stop infection.' Herpes is most commonly transmitted from a carrier to a person without herpes by touching a cold sore, which actively produces or 'sheds' the virus. However, it can cause genital herpes by spreading through oral sex. HSV-1 leads to painful blisters around the lips and mouth, skin and genitals. When the virus infects a person, it may travel up to a cluster of sensory nerves in the brain and remain dormant there for months or even years after the initial infection. But in times of stress, severe fatigue, or changes to the immune system, the virus can reactivate, multiply, and travel back to the skin through nerve fibers. These stressful times can result in new blisters in the same area as the initial infection. The new study, published Thursday in Nature Communications, looked at human A549 cells, which are caused by the cancer lung carcinoma. The cells were then infected with HSV-1 representing one, three and eight hours post infection. Researchers found after eight hours, HSV-1 had occupied 70 percent of the cells, suggesting it would take less than a day for the virus to completely overtake cell DNA and spread. Dr Esther Gonzalez Almela, first study author, said: 'HSV-1 is an opportunistic interior designer, reshaping the human genome with great precision and choosing which bits it comes into contact with. 'It's a novel mechanism of manipulation we didn't know the virus had to exploit host resources.' The researchers then tried to suppress topoisomerase I, which relaxes DNA and makes it easier for it to replicate. They found this 'hindered viral replication.' The team wrote that suppressing the enzyme stops HSV-1 from progressing, suggesting it could be most beneficial for those in later stages of infection. Topoisomerase inhibitors are sold under names like etoposide, irinotecan and topotecan to slow the growth of lung, colorectal, ovarian and testicular cancers, among others. Some are also used to treat multiple sclerosis, a progressive neurological disorder that attacks the spinal cord, by reducing central nervous system inflammation. They can be given as either pills or intravenously for anywhere from $8 to $61 depending on the method.
The Guardian
39 minutes ago
- The Guardian
Inter Miami v Porto: Club World Cup 2025 live updates
Update: Date: 2025-06-19T18:10:18.000Z Title: Hello and welcome Content: Alexander will be here shortly. In the meantime, read up on the latest at the Club World Cup, including yesterday's bizarre Juventus/Donald Trump press availability in which two US national team players were made to look very uncomfortable:
Daily Mirror
41 minutes ago
- Daily Mirror
Enzo Maresca shares Chelsea transfer plan as Mykhailo Mudryk faces four-year ban
Mykhailo Mudryk missed the second half of last season and Chelsea are openly looking for a new winger, having already had two bids turned down for Borussia Dortmund's Jamie Gittens Enzo Maresca is already planning for life after Mykhailo Mudryk. Chelsea winger Mudryk is facing a four year ban after being charged by the Football Association for a doping offence after failing a drugs test last November. Mudryk - nicknamed Mischa - missed the second half of last season and Chelsea are openly looking for a new winger in the summer window. They have already had two bids turned down for Borussia Dortmund 's Jamie Gittens. Chelsea boss Maresca said: 'We had already one entire season already without Mischa. We are going to decide to go for a winger. 'In both cases, we have Noni Madueke and Pedro Neto as proper wingers, then we try to adapt with Tyrique George. It's a position we need to improve.' Ukraine star Mudryk has promised to clear his name while he also showed up announced in Wroclaw for the Conference League final. Maresca insisted that he would back his player until told differently as the drugs case now goes through process as the winger - who cost £89m in January 2023 - waits to hear his fate. Maresca said: 'I spoke with Mischa in Poland when we played the Conference League Final. We haven't spoken since. There is nothing I can add. I don't have more information. "Mischa is a Chelsea player. Until he is not, I will trust. It's not just about Mischa. It's in general with all the players.' But Maresca insisted that England winger Madueke was not for sale this summer despite links with him leaving Stamford Bridge and he was also dropped last season amid criticism over his poor levels in training. Chelsea also have Estevao Willian, 18, arriving at Stamford Bridge and is regarded as one of Brazil's best prospects. He is at the Club World Cup but with Palmeiras and has already won five senior caps. Maresca added: 'Noni is our player. In this moment, you can read many speculation [about players]. We consider Noni as our player for next season.' Meanwhile, Chelsea star Andrey Santos is expecting a hot reception against Flamengo - and he is ready for one of football's great rivalries. Santos, 21, was born in Rio de Janeiro, played for Vasco da Gama and likened their rivalry with Flamengo to Argentina and Brazil. Brazil midfielder Santos said: 'Of course, against Flamengo there's always extra motivation, especially because I was playing for a rival team. 'Flamengo and Vasco da Gama is like Argentina and Brazil. It's a big derby so we have to improve in this game, but I'm so happy to play against Flamengo again. I'm looking forward to it. 'It's hard because I played for Flamengo's rival, so of course when I'm on the pitch they're probably not going to say nice things about me! It's probably going to happen but it's football, it's normal for me. 'I know there are many people from Brazil here and the support of their fans is amazing, but we have to be constant and to do our work.' Santos was signed by Chelsea in 2023, was loaned back and then had a frustrating loan spell at Nottingham Forest before going to Strasbourg last year. That was a big learning year for the Brazil international and he hopes that experience can help elevate him into being a big player for Chelsea this season. He added: 'In the past two years, things feel so different. In two years a lot of things have happened. Now I have my son, I'm married now, my whole life has changed and I have more experience. 'Last season for me was amazing because it wa say first season in Europe, first season competing in Europe and I scored 11 goals, four assists and we went to the Conference League and, for me, it was amazing. 'It's good to be here with my teammates, of course I enjoy the time here. This time is important for me, I enjoy being with my friends and getting to know my teammates more. 'Expectations are the best here, that we can work well, end the week well so that we can arrive at the game well and leave with a positive result.' Join our new WhatsApp community and receive your daily dose of Mirror Football content. We also treat our community members to special offers, promotions, and adverts from us and our partners. If you don't like our community, you can check out any time you like. If you're curious, you can read our Privacy Notice.
